This study investigates advanced pancreatic cancer. It explores the use of gemcitabine and nab-paclitaxel venous injection combined with transcatheter arterial infusion.
The study evaluates the effectiveness and safety of this treatment combination. It focuses on understanding the potential benefits and any side effects associated with this approach.
- Who can participate: Adults aged 18 to 80 years with confirmed advanced pancreatic adenocarcinoma who have not received major anti-cancer treatments may participate. Participants must have an ECOG performance status of 0-2 and meet specific health criteria.
- Study details: Participants will receive a combination of venous injection and arterial infusion treatments.